Provided by Tiger Trade Technology Pte. Ltd.

Replimune Group Inc.

13.42
+0.38002.91%
Post-market: 13.420.00000.00%19:30 EDT
Volume:2.02M
Turnover:26.81M
Market Cap:1.26B
PE:-4.25
High:13.44
Open:12.96
Low:12.79
Close:13.04
52wk High:16.33
52wk Low:1.50
Shares:94.22M
Float Shares:77.49M
Volume Ratio:1.05
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1550
EPS(LYR):-3.3828
ROE:-134.29%
ROA:-51.30%
PB:11.97
PE(LYR):-3.97

Loading ...

Replimune Shares Plummet to All-Time Low as FDA Rejection Muddies Path Forward

Dow Jones
·
Apr 13

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:52 AM

Reuters
·
Apr 13

Replimune Group Cut to Neutral From Overweight by Cantor Fitzgerald

Dow Jones
·
Apr 13

Replimune Shares Decline 66.3% as at Least Six Brokerages Downgrade Stock After Co's Drug Fails to Win FDA Nod

THOMSON REUTERS
·
Apr 13

BUZZ-Street View: Tough path ahead for Replimune after second FDA setback on melanoma drug

Reuters
·
Apr 13

Top Premarket Decliners

MT Newswires Live
·
Apr 13

Replimune Group Inc : Bmo Cuts to Underperform From Market Perform; Cuts Target Price to $1 From $11

THOMSON REUTERS
·
Apr 13

Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19

MT Newswires Live
·
Apr 13

Replimune Group Cut to Sell From Buy by HC Wainwright & Co.

Dow Jones
·
Apr 13

Replimune downgraded to Sell from Buy at H.C. Wainwright

TIPRANKS
·
Apr 13

BUZZ-Replimune slumps after FDA drug rejection prompts downgrades

Reuters
·
Apr 13

Replimune Shares Decline 58% Premarket After at Least Two Brokerages Downgrade Stock After Advanced Skin Cancer Fails to Win FDA Nod

THOMSON REUTERS
·
Apr 13

Replimune Group Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Apr 13

Replimune downgraded to Hold from Buy at Jefferies

TIPRANKS
·
Apr 13

BRIEF-Replimune Group Disagrees With FDA About Whether Rp1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients

Reuters
·
Apr 11

Replimune says FDA’s CRL for RP1 ‘disappointing’

TIPRANKS
·
Apr 11

Replimune says FDA ‘appears to have contradicted their positions’ in CRL

TIPRANKS
·
Apr 11

Replimune Group: We Have No Choice but to Eliminate Jobs, Including Substantially Scaling Back Our U.S. Based Manufacturing Operations

THOMSON REUTERS
·
Apr 11

Replimune: Based on FDA Feedback, Started Ignyte-3 to Satisfy Regulatory Requirement That Confirmatory Study Be Underway for Accelerated Approval

THOMSON REUTERS
·
Apr 11

Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

TIPRANKS
·
Apr 11